MedTrace Logo

Pilot Trial of XFBD, a TCM, in Persons With COVID-19

NCT04810689 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-12-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to document the safety of taking traditional Chinese medicine (TCM) in patients with COVID-19 and to gain information to determine whether a study with TCM can be conducted. The study will test a traditional Chinese medicine that has been made into a granule formulation called Xuanfei Baidu Granules.

Conditions

  • Covid19

Interventions

DRUG

Xuanfei Baidu Granules

Xuanfei Baidu granules is a prescription of 13 herbal medicinals made into dissolvable granules for oral intake

OTHER

Placebo

Placebo for Xuanfei Baidu granule made into dissolvable granules for oral intake

Sponsors & Collaborators

  • Darcy Spicer

    lead OTHER

Principal Investigators

  • Darcy V Spicer, MD · Keck Medicine of USC

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2022-06-20
Completion
2022-06-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04810689 on ClinicalTrials.gov